12,255 followers
RT @FrontOncology: New research: Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines thera…
RT @FrontOncology: New research: Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines thera…
New research: Positive response to trastuzumab deruxtecan in a patient with HER2-mutant NSCLC after multiple lines therapy, including T-DM1: a case report: Human epidermal growth factor 2 (HER2) mutations are uncommon in non-small cell lung… https://t.co/x